Altimmune, Inc. today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.
GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc., (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update.
Conference Call Information:
| Date: | Thursday, May 12 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | (800) 225-9448 |
| International Dial-in: | (203) 518-9708 |
| Conference ID: | ALTQ122 |
| Webcast: | https://edge.media-server.com/mmc/p/j5i9f735 |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
